Heifers (n=136) from 5 herds were treated with a commercially available β-lactam intramammary (IMM) antibiotic preparation containing cephapirin sodium at 10–21 d prior to anticipated parturition to evaluate the risk of antibiotic residues occurring in milk postpartum and to determine factors associated with antibiotic residues and IMM pathogen presence in milk postpartum. Mammary secretions collected from quarters before antibiotic administration and during weeks 1, 2 and 3 postpartum were analyzed for mastitis pathogens. Composite milk was collected at milkings 3, 6 and 10 postpartum and analyzed for β-lactam residues using a microbial inhibition antibiotic residue screening test. Antibiotic residues were confirmed with β-lactamase treatment and re-tested for residues. Residues were detected in 28.0, 8.82 and 3.68% of milk samples obtained at the third, sixth, and tenth milking postpartum, respectively. Increases in interval between prepartum antibiotic therapy and parturition and an increase in the postpartum interval to sampling were associated with a decrease in risk of antibiotic residues. The presence of antibiotic residues in milk at the third milking was associated with a reduced risk for IMM pathogen prevalence in the first 21 d postpartum. Lower somatic cell counts, an increase in mean milk yield over 200 days in milk and a reduction in IMM pathogen prevalence were associated with the presence of an antibiotic in milk postpartum. Screening milk for antibiotic residues in milk postpartum following prepartum antibiotic therapy in heifers is recommended to reduce the risk for antibiotic residue contamination of milk.

This report describes the development and implementation of a statewide mycoplasma mastitis control program for Louisiana. Mycoplasma mastitis is a unique form of mastitis caused by several species of the genus Mycoplasma. The highly contagious nature of these infections coupled with difficulties in diagnosis and therapy often contributes to catastrophic herd outbreaks resulting in severe economic loss. Mycoplasma mastitis was first detected in Louisiana in September 2002. As a result of this initial outbreak and because of the potential for serious economic loss associated with this type of mastitis, all dairy farms in the state were screened for mycoplasma mastitis. This screening identified an additional 12 dairy farms (2.8%) as having Mycoplasma species in bulk tank milk. The statewide survey prompted a rapid and unique response from several diverse groups within the state to address the problem. As a result of these meetings, a program was designed with input from all groups involved to combat this threat. Monthly bulk milk analysis revealed Mycoplasma species in at least 1 bulk tank for 12 of the 20 mo tested. Twenty-four bulk milk samples were positive for mycoplasma over the course of the monthly portion of the program. In 2006 the program shifted to a quarterly samplingof bulk tanks. Results from 545 bulk tanks cultured revealed 3 bulk tanks positive for Mycoplasma species (0.05%) during 2006. The implementation of an education, monitoring, and control program combining monthly bulk tank culture with restrictions on sale of cattle from confirmed positive herds has reduced the incidence of this type of mastitis in Louisiana and heightened awareness and adoption of control measures.

Preparturient heifers (n = 561) from 9 herds in 6 US states and 1 Canadian province were enrolled in a study to test the hypothesis that prepartum intramammary therapy would cure existing intramammary infections (IMI) and lead to increased milk production, reduced linear somatic cell count (LSCC), and improved reproductive performance. Mammary secretions were collected 10 to 21 d before expected calving from each quarter. Heifers were then assigned by identification number to receive intramammary therapy consisting of infusion of one tube per mammary quarter of a lactating cow commercial antibiotic preparation containing cephapirin or to a nontreated control group. Overall, 34.1% of mammary quarters were infected with a mastitis pathogen before parturition and 63.4% of heifers had at least one mammary quarter infected. The coagulase-negative staphylococci (CNS) caused the majority (74.8%) of prepartum IMI. Coagulase-positive staphylococci, environmental streptococci, and coliforms accounted for 24.5% of prepartum infections. Treatment had a significant effect on the cure rate of infected mammary quarters. Mammary quarters that were infected prepartum and treated with antibiotics had a 59.5% efficacy of cure rate and the percentage reduction in heifers with IMI was 51.9. Control quarters had a spontaneous cure rate of 31.7%. Treatment did not significantly affect milk production or LSCC in the first 200 d of lactation; however, there was a significant treatment by herd interaction for milk production. Quarters cured of either CNS or major pathogens had a lower LSCC in the first 200 d of lactation. No significant effect on services per conception or days open between treatment and control groups was observed. This trial demonstrated that prepartum intramammary antibiotic therapy did reduce the number of heifer IMI postpartum. Milk production, LSCC, and reproductive performance during the first 200 d of the first lactation were not significantly affected by treatment. Given these results, use of prepartum intramammary antibiotic therapy in heifers as a universal strategy to increase milk production in first-lactation dairy cows may not be warranted.

An experimental challenge trial was performed against Staphylococcus aureus and Streptococcus agalactiae following the procedures recommended by the National Mastitis Council. The efficacy of two teat dips, product 1 (Bovadine with I-Tech II) and product 2 (Bovadine with I-Tech, used as a positive control), was determined. Both teat dips contain 1% iodine and 10% glycerin. Product 1 established an 89.7% reduction in infections against Staph. aureus and 73.1% reduction in infections against Strep. agalactiae. Product 2 demonstrated an 86.2% reduction in infections against Staph. aureus and 78.4% reduction in infections against Strep. agalactiae. Teat skin and teat ends were evaluated before and after the trial. No significant change in teat condition was observed for either product.

Two antibiotic preparations, tilmicosin and ceftiofur, were tested intramammarily and parenterally against Staphylococcus aureus mastitis in lactating cows. Neither product was effective as a lactating cow treatment at the doses and durations of treatment tested. Injection or infusion of tilmicosin and infusion of ceftiofur resulted in reductions of bacteria present in milk; however, only one quarter treated with infusion of tilmicosin was cured, and no cures were observed for the other treatments. Somatic cell counts were transiently reduced by infusion of ceftiofur and by infusion and injection of tilmicosin; however, they returned to pretreatment values by 28 d posttreatment.

Initial studies to determine the prevalence of mastitis in heifers of breeding age and in pregnant dairy heifers demonstrated that IMI were present in 97% of heifers and 75% of quarters. The most common isolates were Staphylococcus aureus, Staphylococcus hyicus, and Staphylococcus chromogenes; SCC ranged from 12.4 to 17.3×106/ml. Approximately 29% of heifers and 15% of quarters exhibited clinical mastitis at breeding age, as evidenced by clots or flakes in mammary secretions. Histologic examination of mammary tissues demonstrated significant reductions in alveolar epithelial and luminal areas and increases in connective tissue stroma and leukocytosis, illustrating limited development and marked inflammation of infected tissues. A one-time infusion of antibiotic for nonlactating cows into infected quarters ≥45 d prepartum reduced incidence of IMI by 59% at calving compared with the pretreatment level; the cure rate for Staph. aureus IMI was >90%. Prophylactic treatment of uninfected quarters ≥45 d prepartum reduced new Streptococcus sp. IMI by 93%. The mean SCC was 50% lower at calving for treated heifers, and milk yield over the first 2 mo of lactation was 10% greater than that of untreated controls. Heifers from herds using fly control had a lower prevalence of IMI than herds without fly control. Prevalences of IMI and SCC in dany heifers were higher than previously realized, but mastitis at calving was controlled by use of therapeutic products for nonlactating cows during pregnancy.

Intramammary infusion of a dry-cow antibiotic preparation containing 300 mg of cephapirin benzathine into 18 Jersey heifers, 10-12 weeks prepartum, resulted in cure rates of existing intramammary infection (IMI) of 96% (24/25), 100% (4/4), and 90% (28/31) for Staphylococcus aureus, Streptococcus species, and Staphylococcus species, respectively. Cure rates of IMI that had been treated with a lactating-cow therapy containing 200 mg cephapirin benzathine at parturition were 62.5% (15/24), 100% (22/22), and 100% (3/3) for Staphylococcus aureus, Streptococcus species, and Staphylococcus species, respectively. Initial somatic cell counts (SCC) of secretions from infected quarters were greater than from uninfected quarters. At 2 months postpartum, the SCC of milk from treated and cured quarters were reduced in comparison with quarters that remained infected. Cephapirin benzathine was present at detectable concentrations in 94, 80, 68, and 61% of treated quarters at 1, 2, 3, and 4 weeks after infusion of the cephapirin dry-cow product, respectively. At parturition, 24% of treated quarters were positive for antibiotic, however, no quarters remained positive for antibiotic at 5 days postpartum. An additional 40 heifers from a commercial herd were sampled and infused in all quarters with the cephapirin dry-cow product at 16-20 weeks prepartum. Cure rates for the commercial herd were 94% (29/31), 94% (16/17), 100% (44/44), and 100% (3/3), respectively, for quarters infected by S. aureus, Streptococcus species, Staphylococcus species, and coliforms.

Interleukin-2, pokeweed mitogen, and lipopolysaccharide were evaluated for their ability to accelerate involution and to stimulate local cellular defenses in the nonlactating bovine mammary gland. Twelve cows were divided into three treatment groups of 4 cows each to receive interleukin-2, pokeweed mitogen, or lipopolysaccharide. One day after drying off, 3 mammary quarters of each cow were infused with 100 micrograms of immunostimulant daily for 21 d; the remaining control quarter received PBS. Secretion samples were collected weekly to determine bacteriologic status, total SCC, and differential cell counts. On d 21, cows were killed, and tissues were collected for microscopy. Overall, SCC were higher in immunostimulated quarters, but only those infused with interleukin-2 were significantly elevated over controls. By wk 3, the percentage of neutrophils decreased in interleukin-2 and pokeweed mitogen quarters over pretreatment values, percentage of macrophages increased in interleukin-2 quarters, and percentage of lymphocytes increased in pokeweed mitogen and lipopolysaccharide quarters. Percentage of alveolar lumina was reduced, and connective tissue stroma increased, in all immunostimulated quarters compared with those of controls, suggesting accelerated involution. Involution was greatest in quarters treated with interleukin-2. Leukocyte infiltration was greater in immunostimulated quarters than in control quarters. Similarly, concentrations of Ig-producing plasma cells were greater in immunostimulated quarters than in control quarters. Quarters infused with interleukin-2 exhibited the greatest concentration of plasma cells, followed by quarters treated with pokeweed mitogen and lipopolysaccharide; IgG1 plasma cells predominated, followed by IgG2, IgA, and IgM. Interleukin-2 accelerated involution and stimulated local antibody production more than did the two mitogens, suggesting a potential role for this cytokine as a general immunostimulant at drying off.

The antimicrobial susceptibility to 11 antibiotics was determined of 358 streptococcal isolates representing six species was determined. All isolates were from milk samples obtained from clinical or subclinical cases of bovine mastitis. Agar disk diffusion zone diameters and minimum inhibitory concentrations were obtained for all isolates. Of the antibiotics tested that are available for mastitis therapy, cephalothin, penicillin, ampicillin, novobiocin, and erythromycin demonstrated acceptable activity against nonenterococcal streptococci, but only penicillin and ampicillin demonstrated moderate activity against Enterococcus faecalis. Enterococcus faecalis demonstrated substantial resistance to cephalothin, erythromycin, gentamicin, streptomycin, and tetracycline, while the nonenterococcal streptococci demonstrated substantial resistance to gentamicin, streptomycin, and tetracycline. Streptococcus uberis demonstrated greater antibiotic resistance than did Streptococcus dysgalactiae, while Aerococcus viridans demonstrated the greatest overall resistance of the nonenterococcal species.